Tag: HMO
-
2‑Fucosyllactose Market
Abstract The 2‑fucosyllactose market is expanding rapidly, driven by rising demand for HMOs in infant formula, functional foods, and dietary supplements. As regulatory approvals broaden and large‑scale fermentation technologies mature,…
-
FSANZ Approves New Source of 2′-Fucosyllactose for Infant Formula: Implications for HMO Suppliers and Manufacturers
Abstract Food Standards Australia New Zealand (FSANZ) has approved Application A1334, permitting the use of 2′-fucosyllactose (2′-FL) produced from a new genetically modified source organism as a nutritive substance in…